The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology

The 2022 OncoAlert Colloquium Day 3: Lung Cancer

The 2022 OncoAlert Colloquium Day 2: GU Oncology

The 2022 OncoAlert Colloquium Day 1: Breast Cancer

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma

Elacestrant shows improved PFS in ER-positive/HER2-negative mBC

ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL

ASH 2022: Multiple myeloma roundup

Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma